To be clear, the word "orforglipron" won't appear on Eli Lilly's ... weight management pill. However, the pharmaceutical firm ran into some trouble two years into developing and testing the drug ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss ... drugs, as of July 1. Zepbound will be excluded. Today in History: May 16, China ...

Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its oral weight-loss drug ... planned launches in China and India bolster ...

Lilly said it is planning to request a re-examination of the CHMP's appraisal of Kisunla, pointing out that the drug has already been approved in the US, China ... Orexigen's weight-loss therapy ...